Tag Archives: Access to Medicines

Drug Regulation Others

Plain Apathy or Sheer Incompetence? Govt. Sets New Lows by Running Out of Child Anti-HIV Drugs


Roughly two years back, Kartik had brought up the role of non-IP factors, specifically government apathy, in impeding “access to medicines”. The discussion came up in the context of National AIDS Control Programme (NACO) facing reverses due to the dwindling of stocks of anti-retroviral medication. Two years hence, the government and its bureaucracy, in a shocking display of indifference towards the children living with HIV, have turned a blind eye towards the running out of stocks of syrup containing the…


Read More »
Others

Latest ‘Access to Medicine Index’ Released


The latest ‘Access to Medicine Index’, a biennial study that ranks the top 20 innovator companies on 7 parameters related to access, has been released for 2016 (for our coverage of the 2008 and 2014 Indices, see here and here). The Index assesses how effectively the top 20 research-based pharmaceutical companies make medicines, vaccines and diagnostics more accessible in the middle and low income countries. It is brought out by ‘The Access to Medicine Foundation’ funded by the UK Department…


Read More »
Drug Regulation Patent

UN High Level Panel Releases a Hard Hitting Report on Access to Medicines and Health Technologies


The UN Secretary-General’s High-Level Panel on Access to Medicines (“Panel”) released its final report (“Report”) last month on the issue of promoting innovation and access to health technologies. It comes close on the heels of the UN Human Rights Council Resolution on Access to Medicines (see our post on it here) and echoes most of the sentiments expressed in the Resolution. The Report itself states that it builds on the “previous and existing work in the field of health technology…


Read More »
Patent

Gilead Releases Statement on EPO’s Sovaldi Decision


Continuing our coverage on the recent Sovaldi patent decision by the European Patent Office (EPO), Gilead sent us a statement clarifying certain details. I reproduce it below: “On October 5, 2016, the EPO’s Opposition Division upheld the European patent (EP 2203462) covering sofosbuvir in amended form. The opposition division reached this considered decision following two days of hearings where the opponents to the granting of this patent were given an opportunity to present all of their arguments contesting its validity….


Read More »
Patent

European Patent Office Amends Gilead’s Patent Claims on Sovaldi


In a major victory for public health, the European Patent Office (EPO) has amended Gilead’s patent claims on Sofosbuvir (branded as Sovaldi), used for the treatment of Hepatitis C. Ruling in an opposition proceeding filed by Medecins du Monde (MdM), the EPO held that Gilead’s patent claims “extended beyond the content of the patent application as filed”. A spokesperson for the EPO told Statnews that some of the patent claims were no longer admissible, and had been changed in scope. The…


Read More »
Patent

DIPP Drags the Dasatinib Compulsory License Drama: A situation of “extreme urgency”?


As our readers may recall, in January 2013, the Ministry of Health and Family Welfare (MoH) had recommended that DIPP declare that a compulsory license (CL) should be granted, under section 92 of the Patents Act, 1970, for three exorbitantly priced anti-cancer drugs – Bristol-Myers Squibb’s Dasatinib (or Sprycel) and Ixabepilone (or Ixempra) and Roche’s Trastuzumab (or Herceptin). Two of these three cases were dropped as Roche allowed its patent on Herceptin to lapse (presumably to avoid the license) and…


Read More »
Patent

Cipla Withdraws Revocation Plea for Novartis’ Onbrez Patents, Informs DIPP in an RTI Reply


Many of our readers may have been wondering about the status of the application that Cipla made to DIPP in October 2014 for revocation of Novartis’ patents for the drug Onbrez. DIPP’s recent reply to an RTI application (RTI) has put an end to this wondering. Mr. Pradeep Kumar, who filed about 27 RTIs between October 2014 and June 2016 seeking the status of this application, was informed by the DIPP on June 13 that the application had been withdrawn…


Read More »
Drug Regulation Patent

UN Human Rights Council Adopts Landmark Resolution for promoting Access to Medicine in Developing Countries


(This post has been co-authored by Swaraj Barooah)  It appears that 30th June 2016 was quite a good day for access! Aside from the developments with the Marrakesh Treaty that Vasundhara recently posted on here, the United National Human Rights Council (UNHRC), in its 32nd Session,  adopted the much awaited Resolution on “Access to medicines in the context of the right of everyone to the enjoyment of the highest attainable standard of physical and mental health” (the Resolution). The Resolution…


Read More »
Drug Regulation Innovation Patent

Grant of Patent to Gilead for Sovaldi Challenged in Delhi High Court


As our readers would recall, we had analyzed the Indian Patent Office’s decision to dismiss the multiple pre-grant opposition claims and consequently approve Gilead’s application for the grant of a patent for its hugely important Hepatitis C drug, Sovaldi, last week. The 58-page decision, which was issued by the Deputy Controller Rajesh Dixit, virtually amounted to a complete U-turn by the Patent Office which had rejected Gilead’s application for Sovaldi last January. The decision came in for sharp criticism, not…


Read More »
Patent

WIPO report on Patents and Access to Medicines generates controversy.


This piece is authored by Rupali Samuel, Analyst, SpicyIP. WIPO published a report on 11th April 2016 titled “Patent-based Analysis of the World Health Organization’s 2013 Model List of Essential Medicines” authored by Reed F. Beall and Amir Attaran of the University of Ottawa that aims to empirically test the effect of patents on access to medicines. Their conclusion is that only 2% of the medicines on the WHO Essential Medicines List are covered by patents so as to block generic…


Read More »